Menu
Search
|

Menu

Close
X

Novus Therapeutics Inc NVUS.OQ (NASDAQ Stock Exchange Capital Market)

4.24 USD
-- (--)
As of Mar 20
chart
Previous Close 4.24
Open --
Volume --
3m Avg Volume 7,460
Today’s High --
Today’s Low --
52 Week High 8.61
52 Week Low 1.52
Shares Outstanding (mil) 9.42
Market Capitalization (mil) 39.95
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-1.072
FY17
-2.753
FY16
-15.094
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.80
Price to Sales (TTM)
vs sector
--
8.99
Price to Book (MRQ)
vs sector
2.18
4.66
Price to Cash Flow (TTM)
vs sector
--
40.60
Total Debt to Equity (MRQ)
vs sector
0.00
17.49
LT Debt to Equity (MRQ)
vs sector
0.00
13.83
Return on Investment (TTM)
vs sector
-59.43
12.11
Return on Equity (TTM)
vs sector
-59.58
13.22

EXECUTIVE LEADERSHIP

Keith Katkin
Chairman of the Board, Independent Director, Since 2017
Salary: --
Bonus: --
Catherine Turkel
President, Since 2017
Salary: $205,769.00
Bonus: $80,000.00
Gregory Flesher
Chief Executive Officer, Director, Since 2017
Salary: $290,000.00
Bonus: $100,000.00
Jon Kuwahara
Senior Vice President - Finance and Administration, Since 2017
Salary: $121,635.00
Bonus: --
Erez Chimovits
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

19900 Macarthur Blvd Ste 550
IRVINE   CA   92612-8426

Phone: +1949.2388090

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.

SPONSORED STORIES